Transfusion dose density affects myelodysplastic syndrome survival

Transfusion dose density affects myelodysplastic syndrome survival

(HealthDay)—Transfusion dose density is an independent prognostic factor for progression-free survival (PFS) in patients with myelodysplastic syndromes treated with red blood cell transfusions (RBCTs), according to a study published online June 6 in Haematologica.

Louise de Swart, M.D., from the Radboud University Medical Center in Nijmegen, Netherlands, and colleagues examined of lower-risk patients with treated with RBCTs. Data were analyzed for 1,267 patients from 16 European countries and Israel.

The researchers found that 317 patients died without progression, and disease progressed in 162 patients. There were significant correlations for PFS with age, EQ-5D index, baseline World Health Organization classification, bone marrow blast count, cytogenetic risk category, number of cytopenias, and country. An inverse association was noted for transfusion dose density with progression-free survival; dose density had an increasing impact on risk up to a dose density of 3 units/16 weeks. After correction for the impact of treatment with erythropoietin agents, lenalidomide, and/or iron chelators, the dose effect continued to increase beyond 8 units/16 weeks.

"The negative association of transfusions on PFS already occurs at low RBCT densities below 3 units per 16 weeks," the authors write. "This indicates that the RBCT dependency in patients transfused at relatively low rates, who are usually considered as untransfused patients, may be considered as an indicator of poor prognosis for progression-free survival."

Several authors disclosed financial ties to the biopharmaceutical industry.


Explore further

ASCO: low-dose chemo benefits advanced gastroesophageal cancer

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2019 HealthDay. All rights reserved.

Citation: Transfusion dose density affects myelodysplastic syndrome survival (2019, June 24) retrieved 20 August 2019 from https://medicalxpress.com/news/2019-06-transfusion-dose-density-affects-myelodysplastic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more